BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 915 filers reported holding BAXTER INTL INC in Q4 2013. The put-call ratio across all filers is 0.90 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $9,512,000 | +73069.2% | 122,670 | +73355.1% | 0.03% | – |
Q3 2020 | $13,000 | -99.5% | 167 | -99.4% | 0.00% | -100.0% |
Q2 2020 | $2,597,000 | -40.8% | 30,167 | -44.1% | 0.01% | -10.0% |
Q1 2020 | $4,384,000 | +62528.6% | 54,000 | +48548.6% | 0.01% | – |
Q4 2018 | $7,000 | -99.7% | 111 | -99.6% | 0.00% | -100.0% |
Q3 2018 | $2,090,000 | -27.8% | 27,111 | -30.9% | 0.01% | -33.3% |
Q2 2018 | $2,895,000 | +44.0% | 39,211 | +26.9% | 0.01% | +33.3% |
Q1 2018 | $2,010,000 | -17.2% | 30,903 | -17.8% | 0.01% | -18.2% |
Q4 2017 | $2,429,000 | +49.2% | 37,581 | +44.9% | 0.01% | +37.5% |
Q3 2017 | $1,628,000 | +3.4% | 25,942 | -0.3% | 0.01% | 0.0% |
Q2 2017 | $1,575,000 | +418.1% | 26,009 | +343.2% | 0.01% | +300.0% |
Q1 2017 | $304,000 | -59.8% | 5,869 | -65.6% | 0.00% | -50.0% |
Q4 2016 | $756,000 | -37.1% | 17,056 | -32.4% | 0.00% | -33.3% |
Q3 2016 | $1,202,000 | +49.5% | 25,243 | +42.0% | 0.01% | +50.0% |
Q2 2016 | $804,000 | +15980.0% | 17,777 | +28572.6% | 0.00% | – |
Q4 2014 | $5,000 | +25.0% | 62 | 0.0% | 0.00% | – |
Q3 2014 | $4,000 | +33.3% | 62 | +77.1% | 0.00% | – |
Q1 2014 | $3,000 | +50.0% | 35 | 0.0% | 0.00% | – |
Q4 2013 | $2,000 | 0.0% | 35 | 0.0% | 0.00% | – |
Q3 2013 | $2,000 | -50.0% | 35 | -44.4% | 0.00% | – |
Q2 2013 | $4,000 | – | 63 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
13D Management LLC | 194,807 | $11,794,000 | 4.18% |
Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |